Kodiak Sciences (KOD) shares were 38% higher pre-bell Thursday after the company said that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.
Navan (NAVN) stock was up 24%, a day after the company reported it swung to fiscal Q4 earnings amid higher revenue.
Noodles (NDLS) shares were 19% higher after the company reported late Wednesday improved Q4 financial results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments